Register of
Medicinal Products

Product class: Authorized package
Medicinal product class: For human use
Package code: 1314919
Name of medicinal product: VINBLASTINE TEVA
Active substances:
Vinblastine
Estonian, English, Latin
ATC code: L01CA01
Dosage form: solution for injection
Route of administration: intravenous use
Strengh: 1mg 1ml
Amount in package: 10ml 1TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: Vinblastine can sometimes be administered in monotherapy but is usually administered in combination with other cytostatic drugs and/or radiotherapy for the following malignancies: malignant non-Hodgkin's lymphoma Hodgkin's disease Advanced carcinoma of the testes Recurrent or metastatic breast cancer (when anthracycline based regimens have failed) Langerhans cell histiocytosis (histiocytosis X)
Safety features: Yes
Summary of product characteristics (SPC):  (last updated July 16, 2020)
Package information leaflet (PIL): EST  (last updated July 16, 2020)
Labelling:  (last updated April 28, 2017)
Last imported to Estonia: July 7, 2023
Marketing authorization holder: Teva Pharma B.V. 
Marketing authorization number: 621209 
Marketing authorization issued on: February 6, 2009 
Marketing authorization expires on: Unlimited 
Marketing authorization procedure type: Decentralised 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Entry/Changing date: February 14, 2024
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere